Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.
Stewart AK, Krishnan AY, Singhal S, Boccia RV, Patel MR, Niesvizky R, Chanan-Khan AA, Ailawadhi S, Brumm J, Mundt KE, Hong K, McBride J, Shon-Nguyen Q, Xiao Y, Ramakrishnan V, Polson AG, Samineni D, Leipold D, Humke EW, McClellan JS, Berdeja JG. Stewart AK, et al. Among authors: humke ew. Blood Cancer J. 2019 Feb 4;9(2):17. doi: 10.1038/s41408-019-0178-8. Blood Cancer J. 2019. PMID: 30718503 Free PMC article. Clinical Trial.
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, Kelley SK, Lu X, Choi YJ, Maslyar D, Humke EW, Burris HA. Liu JF, et al. Among authors: humke ew. Ann Oncol. 2016 Nov;27(11):2124-2130. doi: 10.1093/annonc/mdw401. Ann Oncol. 2016. PMID: 27793850 Free article. Clinical Trial.
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF. Banerjee S, et al. Among authors: humke ew. Ann Oncol. 2018 Apr 1;29(4):917-923. doi: 10.1093/annonc/mdy023. Ann Oncol. 2018. PMID: 29401246 Free article. Clinical Trial.
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA 3rd. Gerber DE, et al. Among authors: humke ew. Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20. Clin Cancer Res. 2020. PMID: 31540980 Clinical Trial.
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Moore KN, Birrer MJ, Marsters J, Wang Y, Choi Y, Royer-Joo S, Lemahieu V, Armstrong K, Cordova J, Samineni D, Schuth E, Vaze A, Maslyar D, Humke EW, Hamilton EP, Liu JF. Moore KN, et al. Among authors: humke ew. Gynecol Oncol. 2020 Sep;158(3):631-639. doi: 10.1016/j.ygyno.2020.05.039. Epub 2020 Jun 11. Gynecol Oncol. 2020. PMID: 32534811 Free article. Clinical Trial.
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
Li C, Takahashi C, Zhang L, Huseni M, Stankovich B, Mashhedi H, Lee J, French D, Anderson JE, Kim D, Howell K, Brauer MJ, Kowanetz M, Yan Y, Humke E, Ebens A, Hampton G, Lackner MR, Hegde P, Jia S. Li C, et al. J Transl Med. 2013 Mar 23;11:76. doi: 10.1186/1479-5876-11-76. J Transl Med. 2013. PMID: 23522020 Free PMC article.
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.
Chandarlapaty S, Dickler MN, Perez Fidalgo JA, Villanueva-Vázquez R, Giltnane J, Gates M, Chang CW, Cheeti S, Fredrickson J, Wang X, Collier A, Moore HM, Metcalfe C, Lauchle J, Humke EW, Bardia A. Chandarlapaty S, et al. Among authors: humke ew. Clin Cancer Res. 2023 Aug 1;29(15):2781-2790. doi: 10.1158/1078-0432.CCR-23-0011. Clin Cancer Res. 2023. PMID: 37261814 Free PMC article. Clinical Trial.
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199.
Wang BT, Kothambawala T, Wang L, Matthew TJ, Calhoun SE, Saini AK, Kotturi MF, Hernandez G, Humke EW, Peterson MS, Sinclair AM, Keyt BA. Wang BT, et al. Among authors: humke ew. Mol Cancer Ther. 2021 Dec;20(12):2483-2494. doi: 10.1158/1535-7163.MCT-20-1132. Epub 2021 Oct 28. Mol Cancer Ther. 2021. PMID: 34711645 Free PMC article.
25 results